Accordingly, we are speculating that, using sirolimus therapy to inhibit 4E-BP1 phosphorylation and cell cycle re-entry as early as the phosphorylated 4E-BP1 and Ki67 was detected in podocyte in minimal change disease (MCD) patients (Figure S5, Figure S6), might be a useful approach to diminish podocyte apoptosis and loss in the initial phases of glomerular injury and thus prevent the formation of sclerotic lesions. The gene discussed is EIF4EBP1; the disease is lipoid nephrosis.